Pharmaceutical

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific

BMS paid $150m upfront to enter a collaborative development deal for bispecific IMA401 with Immatics in 2021.

Sep 18, 2024 - 04:00
ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific
BMS paid $150m upfront to enter a collaborative development deal for bispecific IMA401 with Immatics in 2021.
Read the original article

Tags:

Previous Article

Podcast: How drones are transforming the clinical supply chain in Africa

Next Article

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast

STAT+: Pharmalittle: White House takes aim at pharma pa...

Dec 7, 2023

RSV vaccines may be linked to small increased risk of developing Guillain-Barré syndrome, data suggest

RSV vaccines may be linked to small increased risk of d...

Feb 29, 2024

CD70 CAR-T by UTC Therapeutics for Follicular Lymphoma:...

Aug 10, 2023